Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06973187
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:05.399009+00:00
Published At
2026-04-22T00:00:00+00:00
Record Updated At
2026-04-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-22"
protocolSection.identificationModule.nctId
"NCT06973187"
protocolSection.identificationModule.officialTitle
"A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.